HLA-F Antibody (YA3943)(PBS only)

Cat. No.: HY-P84246A: Ficha de datos User Guide for Antibodies
FAQs
Technical Support

HLA-F Antibody (YA3943) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to HLA-F.

Para uso exclusivo en investigación. No vendemos a pacientes.

Tamaño		Stock
50 μL		Obtener un presupuesto
100 μL		Obtener un presupuesto

* Seleccione Cantidad antes de agregar artículos.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Descripciòn

Descripciòn

HLA-F Antibody (YA3943) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to HLA-F.

Host

Mouse

Peso molecular

Predicted band size: 39 kDa;

Observed band size: 40-50 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human, Mouse, Rat

SwissProt ID

P30511

Gene ID

3134 [NCBI]

Immunogen

Purified recombinant fragment of human HLA-F (AA: 22-305) expressed in E. Coli.

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500-1:2000
FC FC: Flow Cytometry	1:200-1:400
ELISA ELISA: Enzyme Linked Immunosorbent Assay	1:10000

Pureza	affinity purified.	Conjugation	Non-conjugated
Isotype	IgG2b

Appearance

Liquid

Formulation

Supplied in PBS, pH 7.4.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Envío

Shipping with blue ice.

Background

Function：Non-classical major histocompatibility class Ib molecule postulated to play a role in immune surveillance, immune tolerance and inflammation. Functions in two forms, as a heterotrimeric complex with B2M/beta-2 microglobulin and a peptide (peptide-bound HLA-F-B2M) and as an open conformer (OC) devoid of peptide and B2M (peptide-free OC). In complex with B2M, presents non-canonical self-peptides carrying post-translational modifications, particularly phosphorylated self-peptides. Peptide-bound HLA-F-B2M acts as a ligand for LILRB1 inhibitory receptor, a major player in maternal-fetal tolerance. Peptide-free OC acts as a ligand for KIR3DS1 and KIR3DL2 receptors (PubMed:28636952). Upon interaction with activating KIR3DS1 receptor on NK cells, triggers NK cell degranulation and anti-viral cytokine production (PubMed:27455421). Through interaction with KIR3DL2 receptor, inhibits NK and T cell effector functions (PubMed:24018270). May interact with other MHC class I OCs to cross-present exogenous viral, tumor or minor histompatibility antigens to cytotoxic CD8+ T cells, triggering effector and memory responses (PubMed:23851683). May play a role in inflammatory responses in the peripheral nervous system. Through interaction with KIR3DL2, may protect motor neurons from astrocyte-induced toxicity (PubMed:26928464)

Subcellular Localization：Cell membrane; Single-pass type I membrane protein; Early endosome membrane; Lysosome membrane

Expression：
Tissue_specificity:Expression in resting B cells (protein level) . Expression in secondary lymphoid organs rich in B cells and T cells (such as tonsils, spleen, and thymus) (PubMed:10605026, PubMed:11169396) . Expression in tonsillar endothelial cells (PubMed:11169396) . Expression on activated lymphocytes (including B cells, NK cells, CD4+ T cells, and memory T cells) (PubMed:20865824, PubMed:27455421) . Expression in spinal motor neurons (PubMed:26928464) .

Induction:Up-regulated in CD4+ T cells upon stimulation via TCR and upon HIV-1 infection

Isoforms & Post-Translational Modification：P30511 has 3 isomers: P30511-1: 39062 Da (predicted); P30511-2: 28588 Da (predicted); P30511-3: 50438 Da (predicted).
N-glycosylated

Subunit：Forms a heterotrimer with B2M and a self-peptide (PubMed:28636952). Binds a diverse number of peptides ranging from 7 to more than 30 amino acids (PubMed:28636952). Peptide-bound HLA-F-B2M interacts with LILRB1 and LILRB2 but not with KIR3DS1 or KIR3DL2; this interaction is direct (PubMed:11169396, PubMed:28636952). The OC form interacts with KIR3DS1, KIR2DS4 and KIR3DL2; this interaction is direct (PubMed:24018270, PubMed:27455421, PubMed:28636952). Interacts with TAP1-TAP2 complex and CALR; this interaction is required for appropriate folding and peptide loading (PubMed:10605026, PubMed:11169396). Interacts with the coat protein complex II and 14-3-3 proteins; these interactions likely control the anterograde ER-to-Golgi transport of HLA-F (PubMed:16709803). HLA-F-B2M complex interacts with the heavy chain of other MHC class I molecules including HLA-A and HLA-E; this interaction may regulate the intracellular trafficking and the stability of peptide-free MHC class I OCs (PubMed:20483783)

Synonyms

HLAF; CDA12; HLA-5.4; HLA-CDA12

Documentación

User Guide for Antibodies (1077 KB)